AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27087153
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg cisatracurium
Trial: 17989152
Drug: Aerosolized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized salbutamol (5 mg)
Trial: 17989152
Drug: Nebulization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of ipratropium bromide (0.5 mg)
Trial: 15309429
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran oil (RBO) with low gamma-oryzanol (0.05 g/d)
Trial: 15309429
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran oil (RBO) with high gamma-oryzanol (0.8 g/d)
Trial: 7577887
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at 25 ng/min per kg ideal body weight for 90 min after fasting for 12, 36, and 72 hours
Trial: 7259326
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion at a dose of 6‐10 ng/kg/min for 72 hours
Trial: 31089768
Drug: PZQ +
RxNorm normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ + KTZ (20 mg/kg PZQ + 200 mg ketoconazole)
Trial: 31089768
Drug: PZQ alone
RxNorm normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ alone (20 mg/kg)
Trial: 26907933
Drug: Bimatoprost Unit
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost Unit Dose Preservative Free (BUDPF)
Trial: 26907933
Drug: Latanoprost Unit
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost Unit Dose Preservative Free (LUDPF)
Trial: 12499320
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g EPA+DHA (4:0)
Trial: 12499320
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g EPA+DHA plus 1 g GLA (4:1)
Trial: 12499320
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g GLA (4:2)
Trial: 12499320
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g GLA (4:4)
Trial: 8869688
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg/day for 3 days)
Trial: 8869688
Drug: Prednisolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (50 mg/day for 3 days)
Trial: 1531552
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (detuned ultrasound and detuned short‐wave diathermy)
Trial: 31074823
Drug: Ustekinumab therapy
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab therapy for 8 weeks or more
Trial: 28658582
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (10 mg.kg‐1 body mass of sodium nitrate)
Trial: 23388533
Drug: Cycloferon (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloferon (in tablets) administered under standard regimen to frequently ill children (FIC)
Trial: 21756323
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg bid (n = 42)
Trial: 21756323
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg bid (n = 40)
Trial: 21756323
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pioglitazone 30 mg and metformin 1.7 g (n = 39)
Trial: 14679315
Drug: Soy-based milk
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-based milk and yoghurt (treatment)
Trial: 2899663
Drug: Feverfew (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feverfew (one capsule of dried feverfew leaves a day for four months)
Trial: 30575345
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (Group 1)
Trial: 27470681
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TA) 1 g loading dose followed by 1 g over 8 hours
Trial: 27470681
Drug: Intravenous 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% normal saline (placebo)
Trial: 15125484
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg, p.o.)
Trial: 3623744
Drug: Dapsone (DDS)
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone (DDS) 100 mg orally in dogs
Trial: 3623744
Drug: Dapsone (DDS)
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone (DDS) 100 mg intravenously in dogs
Trial: 3623744
Drug: Dapsone (DDS)
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone (DDS) 50 mg intravenously in healthy volunteers
Trial: 3623744
Drug: Dapsone (DDS)
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone (DDS) 50 mg orally in healthy volunteers
Trial: 27598379
Drug: Progressive Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive Muscle Relaxation (PMR) technique, performed daily over eight weeks.
Trial: 24119823
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of methylphenidate (MPH)
Trial: 24119823
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of levodopa (LEV)
Trial: 17846935
Drug: No primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No primary antibiotic treatment
Trial: 12586130
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg/day and warfarin (INR 2.0-2.5)
Trial: 12586130
Drug: Aspirin groups
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin groups combined (n=129)
Trial: 28846767
Drug: 50 µg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg/d transdermal 17β‐estradiol (t‐E2)
Trial: 28846767
Drug: 0.45 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/d oral conjugated equine estrogens (o‐CEE)
Trial: 16197583
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g isomalt daily
Trial: 16197583
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g sucrose daily (Control)
Trial: 9987085
Drug: Selective endothelin
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective endothelin A (ETA) receptor antagonist BQ-123 (3 mg/hr)
Trial: 9987085
Drug: Mixed endothelin-converting
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed endothelin-converting enzyme and neutral endopeptidase inhibitor phosphoramidon (30 nmol/min)
Trial: 9987085
Drug: Selective neutral
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective neutral endopeptidase inhibitor thiorphan (30 nmol/min)
Trial: 2106274
Drug: Flumazenil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.4 mg
Trial: 2106274
Drug: Naloxone 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.05 mg
Trial: 29642094
Drug: SPS-MC (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPS-MC (sodium picosulphate/magnesium citrate preparation)
Trial: 29642094
Drug: PEG-Asc+B (2-l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-Asc+B (2-l ascorbic-acid-enriched polyethylene glycol solution plus bisacodyl pretreatment)
Trial: 23345581
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC‐M4)
Trial: 23345581
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of TBC‐M4 alone
Trial: 21138518
Drug: Epoetin α
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin α (target Hb 9.5 to 11.0 g/dL and 11.5 to 13.0 g/dL)
Trial: 12709347
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice a day orally for 7 days)
Trial: 12709347
Drug: Chloramphenicol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (500 mg four times a day orally for 14 days)
Trial: 9003953
Drug: Serum alpha‐L‐fucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum alpha‐L‐fucosidase activity
Trial: 1469466
Drug: BCNU combined
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU combined with vincristine intravenously and procarbazine orally, followed by radiation therapy
Trial: 21211380
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg once daily for 8 weeks
Trial: 21211380
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg once daily and Tolterodine 2 mg twice daily for 8 weeks
Trial: 16123895
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment (fibre)
Trial: 12382386
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine (1 ml)
Trial: 12382386
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine (2 ml)
Trial: 12382386
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine (1 ml)
Trial: 12382386
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine (2 ml)
Trial: 7027892
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg, given as 2 tablets o.m.
Trial: 7027892
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg o.m. monotherapy
Trial: 31735245
Drug: Cognitive-Behavioral Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Group Therapy (CBGT)
Trial: 29177434
Drug: AZD4547 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off schedule of a 21-day cycle
Trial: 29177434
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 administered weekly on days 1, 8, and 15 of a 28-day cycle
Trial: 25528898
Drug: ESL 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESL 1,200 mg
Trial: 25528898
Drug: ESL 800
RxNorm normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ESL 800 mg
Trial: 23450315
Drug: Self-administered Epworth
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered Epworth Sleepiness Scale (ESSs)
Trial: 23450315
Drug: Physician-administered Epworth
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician-administered Epworth Sleepiness Scale (ESSp)
Trial: 19755930
Drug: Proliferative response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Proliferative response to vaccine antigens
Trial: 15188169
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alpha (9 million units)
Trial: 15188169
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon alpha (3 million units)
Trial: 11473558
Drug: s-ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s-ketamine (0.5 mg kg‐1)
Trial: 11367689
Drug: recombinant alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant alpha-2a interferon (1 million units daily for 6 days)
Trial: 11367689
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 and Vitamin B1 (conventional dose for 6 days)
Trial: 3415884
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 5 ml in sitting position
Trial: 3415884
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 5 ml in lateral position
Trial: 3415884
Drug: Hyperbaric solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric solution in sitting position
Trial: 3415884
Drug: Hyperbaric solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric solution in lateral position
Trial: 28873511
Drug: UC‐MSCs (1×10^6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC‐MSCs (1×10^6 UC‐MSCs/kg, four peripheral intravenous infusions, one infusion per week)
Trial: 27029459
Drug: 50-50% N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-50% N2 O + i.v. remifentanil 0.1 μg/kg/min
Trial: 27029459
Drug: remifentanil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 0.1 μg/kg/min
Trial: 24941840
Drug: Shenkangling Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenkangling Decoction + Western medicine
Trial: 15060505
Drug: Ephedrine plus
RxNorm normalized name: EPHEDRINE HYDROCHLORIDE 12.5 mg / GUAIFENESIN 200 mg ORAL TABLET [Red Label Ephedrine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine plus caffeine (25 mg ephedrine, 200 mg caffeine)
Trial: 15060505
Drug: Ephedrine alone
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine alone (25 mg)
Trial: 15060505
Drug: Caffeine alone
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine alone (200 mg)
Trial: 15060505
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg) compared with ephedrine (25 mg)
Trial: 9362403
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose conjugated estrogen (1.25 mg)
Trial: 9362403
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose conjugated estrogen (10 mg)
Trial: 1543426
Drug: Baclofen (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (20mg for one week after titration)
Trial: 16982783
Drug: Itraconazole as
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole as NanoCrystal formulation (NCF) 100 mg
Trial: 16982783
Drug: Itraconazole as
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole as NanoCrystal formulation (NCF) 300 mg
Trial: 16982783
Drug: Itraconazole as
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole as NCF (200 mg)
Trial: 16982783
Drug: Itraconazole as
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole as HPBCD solution (200 mg)
Trial: 11966762
Drug: Chromium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium (200 microg) and Copper (3.0 mg) supplementation for 12 weeks
Trial: 11966762
Drug: Copper (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper (3.0 mg) supplementation for 12 weeks
Trial: 11966762
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.394 g lactose)
Trial: 10088136
Drug: THA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THA (25 and 50 mg, orally)
Trial: 10150323
Drug: Oral amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amitriptyline
Trial: 1704168
Drug: Propafenone 300
RxNorm normalized name: propafenone 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 300 mg b.i.d.
Trial: 1704168
Drug: Quinidine slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine slow-release 800 mg b.i.d.
Trial: 17067504
Drug: Non-fractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fractionated heparin (nFH) at 5-7 U/kg/hour
Trial: 17067504
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of epoprostenol and nFH at 2.5 U/kg/hour
Trial: 11281369
Drug: Hydrocortisone 15
RxNorm normalized name: hydrocortisone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 15 mg per day
Trial: 11281369
Drug: Hydrocortisone 20
RxNorm normalized name: hydrocortisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 20 mg per day
Trial: 11281369
Drug: Hydrocortisone 30
RxNorm normalized name: hydrocortisone 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 30 mg per day
Trial: 6750118
Drug: Indomethacin capsules
RxNorm normalized name: Indomethacin Capsules
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin capsules (50 mg for the first 5 days, 100 mg for the second 5 days)
Trial: 6750118
Drug: Indomethacin suppositories
RxNorm normalized name: Indomethacin Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppositories (50 mg for the first 5 days, 100 mg for the second 5 days)
Trial: 27654816
Drug: Dexmedetomidine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine as a primary sedative (n = 138; 11%)
Trial: 27654816
Drug: Dexmedetomidine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine as a secondary sedative (n = 280; 23%)
Trial: 27654816
Drug: Dexmedetomidine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine as a periextubation agent (n = 178; 15%)
Trial: 18990967
Drug: Tiotropium 8,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 8, 16, or 32 microg administered once daily via Respimat SMI for 14 days
Trial: 18990967
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in both studies
Trial: 1464208
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hyoscine-N-butylbromide
Trial: 1464208
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hyoscine-N-butylbromide
Trial: 1464208
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg hyoscine-N-butylbromide
Trial: 31551219
Drug: Oxycodone (O)
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone (O) alone postoperatively
Trial: 31551219
Drug: Dexmedetomidine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine combined with oxycodone (DO) postoperatively
Trial: 20205269
Drug: Optimal weighted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal weighted combination of pseudo-likelihood estimators
Trial: 18609291
Drug: Hydration scheme
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration scheme of 290 ml of water/m2
Trial: 18609291
Drug: Hydration scheme
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration scheme of 580 ml of water/m2
Trial: 11858378
Drug: Gemfibrozil (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (administered to 7 patients for 4 months)
Trial: 11858378
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered to 5 patients for 4 months)
Trial: 10360847
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) - additional 20 mg oral morphine (10 mg at 12-h intervals)
Trial: 10360847
Drug: Dipyrone Group
RxNorm normalized name: dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone Group (DG) - 500 mg oral dipyrone at 6-h intervals